Close menu




July 17th, 2024 | 07:30 CEST

Siemens Energy share down 50%? Now time to buy Rheinmetall, Bayer, and Saturn Oil + Gas?

  • Mining
  • Oil
  • Defense
  • Pharma
  • renewableenergies
Photo credits: pixabay.com

Can the Siemens Energy share halve in value? At least, that is what the analysts at Bernstein think, who have set a price target of EUR 15. After a strong rally, the focus is now back on the Company's problem areas, such as India. Rheinmetall, on the other hand, is recommended as a "Buy". Can the armaments group thus end its sideways movement? In an initial study, analysts see around 50% upside potential for Saturn Oil & Gas. The oil company intends to significantly increase its free cash flow in the coming years but is considered undervalued compared to its peers. Some analysts see even more potential. Analysts are cautious about Bayer shares. In addition to the well-known legal disputes, operational issues are also a burden.

time to read: 2 minutes | Author: Fabian Lorenz
ISIN: RHEINMETALL AG | DE0007030009 , BAYER AG NA O.N. | DE000BAY0017 , Saturn Oil + Gas Inc. | CA80412L8832

Table of contents:


    Saturn Oil & Gas: 50% upside potential conservative?

    The National Bank of Canada has initiated coverage on Saturn Oil & Gas. In their initial study, the analysts praise the management of the Canadian oil producer for the massive expansion of production volumes through acquisitions in recent years.

    Saturn Oil & Gas is now a broadly diversified company with a production of 39.000 barrels of oil equivalent (BOE) per day. This translates into a stable free cash flow for shareholders. The expected further increase in the free cash flow yield due to further growth and debt reduction argues in favour of a rising share price. Saturn aims to produce around 50,000 BOE per day in the medium term.

    Saturn Oil & Gas is currently trading at a 1.8x EV/DACF multiple for 2025e. The valuation of the peer group is 2.3x. This discount should resolve over time. Therefore, the stock is included in the coverage with a price target of CAD 4.00. At a current price of around CAD 2.70, this represents a potential upside of around 50%. The analysts see further upside potential if the management continues to pursue its growth and debt reduction strategy. The analysts at National Bank of Canada are therefore rather conservative. Eight Capital recently raised its price target for Saturn Oil & Gas from CAD 4.45 to CAD 7.35.

    Rheinmetall: Order intake above expectations?

    Analysts also have a positive overall view of Rheinmetall shares. However, after the strong share price performance in recent years, the air is understandably getting thinner. JPMorgan recently issued a "Buy" recommendation ("Overweight"). The order intake in the second quarter is likely to have exceeded analysts' estimates, and the latest long-term orders, such as for the new Panther battle tank from Italy or an ongoing tender for trucks in the US, are not yet sufficiently reflected in the revenue and earnings forecasts. The analysts, therefore, raised their price target for Rheinmetall shares from EUR 600 to EUR 680.

    Deutsche Bank is somewhat more cautious. The analysts praised the significant increase in incoming orders, and the outlook for the year as a whole is also likely to be confirmed in the upcoming quarterly report. However, the share has performed well and is not considered cheap. With a price target of EUR 510, the analysts currently see no upside potential.

    Bayer: Problems in the agricultural business?

    The analysts at UBS were also unable to do more than "Neutral" on Bayer shares this week. Despite a target price of EUR 32, which is a good deal higher than the current level of EUR 26, analysts believe that the DAX-listed company will exceed the market's EBITDA expectations in the specialities segment. In the agricultural sector, however, Bayer could miss market estimates.

    Jefferies had previously pointed out the challenging environment in the agricultural sector. The declining revenues from the anticoagulant Xarelto should also not be underestimated. This makes it all the more crucial for Bayer to further reduce costs. Overall, the analysts expect Bayer's earnings in 2024 to reach the lower end of the forecast range at most.


    Rheinmetall is currently overwhelmed with orders, but the necessary capacities often must be created first, and the share has already performed very well. Saturn Oil & Gas seems to offer more opportunities at the moment, especially as the Canadian oil company is likely to be one of the winners of a Donald Trump election victory in the US. Cost savings amid numerous legal disputes and operational problems are not compelling reasons to buy a share like Bayer.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Armin Schulz on November 18th, 2026 | 05:30 CET

    Pharma Turnaround Stocks Under Review: Evotec, Vidac Pharma and Novo Nordisk – Restructuring, Clinical Trial Results and Outlook

    • Evotec
    • Vidac Pharma
    • Novo Nordisk
    • Drug discovery
    • Biotech
    • Pharma
    • Cancer
    • Oncology
    • Warburg effect
    • Obesity
    • Diabetes
    • Weight-loss pill

    Between November 4 and 9, three pharma and biotech stocks released news that suggests a turning point. At one, the quarterly loss before exceptional items narrowed; at the second, initial data from a placebo-controlled trial are available; and the third has raised its full-year guidance. These are not yet proof of a lasting turnaround, but they are verifiable signs of progress. If this trajectory can be maintained, hope could soon turn into substance. We therefore take a closer look at Evotec, Vidac Pharma and Novo Nordisk to see which has turnaround potential.

    Read

    Commented by Armin Schulz on November 17th, 2026 | 19:35 CET

    Bayer, Cardiol Therapeutics, Novartis – Biotech stocks and pharmaceutical giants in the race for the heart

    • Bayer
    • Cardiol Therapeutics
    • Novartis
    • Heart disease
    • Asundexian
    • Pharma
    • Pericarditis
    • CardiolRx
    • Leqvio

    Created and Published on Behalf of Cardiol Therapeutics

    Cardiology is one of the most exciting fields in the pharmaceutical industry. Four days in Chicago have shown just how much is happening in cardiovascular medicine. From November 6 to 9, pharmaceutical giants and small biotech companies gathered at the American Heart Association Scientific Sessions annual congress with a shared goal: to improve care for patients with cardiovascular disease. The major players bring experience and capital, while smaller companies often contribute fresh ideas. When a company succeeds in securing regulatory approval, investors stand to benefit. This interplay is precisely what makes the market so interesting for investors. We therefore take a closer look at Bayer, Cardiol Therapeutics, and Novartis.

    Read

    Commented by Jens Castner on November 17th, 2026 | 05:33 CET

    Nvidia, Micron Technology, Power Metallic Mines and Rheinmetall in a sell-off: Who can turn things around?

    • AI
    • Semiconductors
    • Critical raw materials
    • Armaments
    • Data centres
    • Copper
    • Gold
    • Silver
    • Mining
    • Defence
    • Nvidia
    • Micron Technology
    • Power Metallic Mines
    • Rheinmetall
    • Platinum
    • Nickel

    Created and Published on Behalf of Power Metallic Mines

    A resignation, a sell-off, a shrug and a lowered forecast: four stocks have taken a heavy beating in recent weeks. At Nvidia, the founder stumbled over private affairs, while at Micron, doubts about the AI boom were enough. Power Metallic Mines is delivering good news, but the market is looking the other way. And Rheinmetall has disappointed investors with full order books but delayed revenues. All four share a large gap between their current share prices and analysts' targets. We take a closer look at the stocks.

    Read